港股升幅扩至近400点 金融地产板块及三桶油领涨 惟石药吐6%失10天线
为期两天的中美高级别经贸磋商正在华盛顿展开，双方都暗示对达成部分协议持谨慎乐观态度，加上爱尔兰总理瓦拉德卡会晤英国首相约翰逊後表示可能於本月31日前达成脱欧协议，投资者对中美贸前景及英国有协议脱欧的乐观情绪升温。亚太区股市今早全面跟随欧美主要市场(普遍升0.6%-1.3%)造好，但升幅均少於1%。
不过，港股继昨天反覆回稳後，今早高开278点或1.1%报25,986(重越10天线)，升幅曾扩至398点，高见26,106，现造26,082，急涨374点或1.5%，成交额261亿元。
蓝筹股几乎全面造好；港交所(00388.HK)、四大内银、中银(02388.HK)、中国平安(02318.HK)、汇控(00005.HK)、恒生(00011.HK)及国寿(02628.HK)升逾1%-2%，後三者升幅最大，分别报58.7元/161.2元/18.38元。至於重磅股腾讯(00700.HK)续升1.7%报324.2元。
地产股全面升逾1%；恒隆地产(00101.HK)、长实集团(01113.HK)、新地(00016.HK)及恒地(00012.HK)更升2.2%-2.9%，分别报18元/52元/110.7元/37.05元。
憧憬中美贸易磋商取得成果，纽约期油涨近2%至53.55美元逾一星期高位，「三桶油」股价均重越10天线，中石化(00386.HK)、中石油(00857.HK)及中海油(00883.HK)升2%-3%，分别报4.64元/4.09元/11.84元。此外，创科实业(00669.HK)由两个低位重越10天线(53.25元)，最高见53.5元，现造53.1元，回升3.1%。煤气(00003.HK)跑赢公用股，报15.26元，回升2%，结束四连跌。
不过，两大药股中生制药(01177.HK)及石药(01093.HK)吐1.8%及6%，分别报10.66元及16.04元，後者失守10天线(16.24元)。国家卫生健康委发布「首批鼓励仿制药目录」，其中包括不少紧缺药品，如甲氨蝶呤、巯嘌呤、维A酸等，共涉及药品33项。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
